A Multicenter, Open Label Single Arm Phase Ib/II Study to Evaluate the Effect and Safety of RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2
Latest Information Update: 10 Jan 2024
At a glance
- Drugs Disitamab vedotin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 04 Jan 2024 Planned End Date changed from 1 Sep 2024 to 1 Sep 2026.
- 04 Jan 2024 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2025.
- 14 Sep 2022 Status changed from not yet recruiting to recruiting.